TNGX
Tango Therapeutics·NASDAQ
--
--(--)
--
--(--)
TNGX fundamentals
Tango Therapeutics (TNGX) released its earnings on Mar 5, 2026: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.29 (YoY +17.14%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.29
+17.14%
Report date
Mar 5, 2026
EPS
Actual | -0.28 | -0.25 | -0.29 | -0.28 | -0.33 | -0.33 | -0.32 | -0.23 | -0.23 | -0.32 | -0.35 | -0.24 | -0.27 | -0.35 | -0.36 | -0.35 | 0.14 | -0.29 |
Forecast | -0.284 | -0.264 | -0.272 | -0.316 | -0.3167 | -0.355 | -0.3517 | -0.326 | -0.337 | -0.274 | -0.31 | -0.345 | -0.3667 | -0.338 | -0.3501 | -0.3438 | -0.0506 | -0.3182 |
Surprise | +1.41% | +5.30% | -6.62% | +11.39% | -4.20% | +7.04% | +9.01% | +29.45% | +31.75% | -16.79% | -12.90% | +30.43% | +26.37% | -3.55% | -2.83% | -1.80% | +376.68% | +8.86% |
Revenue
Actual | 6.79M | 5.72M | 5.76M | 5.77M | 6.92M | 6.41M | 5.77M | 14.60M | 10.73M | 5.43M | 6.47M | 19.88M | 11.61M | 4.12M | 5.39M | 3.18M | 53.81M | 0 |
Forecast | 6.51M | 6.57M | 5.83M | 5.66M | 5.64M | 6.32M | 6.77M | 7.19M | 7.59M | 8.24M | 7.50M | 7.63M | 8.07M | 8.02M | 6.73M | 6.70M | 53.80M | 500.40K |
Surprise | +4.32% | -13.06% | -1.31% | +1.97% | +22.64% | +1.44% | -14.83% | +103.08% | +41.40% | -34.12% | -13.76% | +160.42% | +43.90% | -48.64% | -19.84% | -52.55% | +0.02% | -100.00% |
Earnings Call
You can ask Aime
What does Tango Therapeutics do and what are its main business segments?What factors drove the changes in Tango Therapeutics's revenue and profit?What is the revenue and EPS growth rate for Tango Therapeutics year over year?What is the market's earnings forecast for Tango Therapeutics next quarter?What is Tango Therapeutics's latest dividend and current dividend yield?Did Tango Therapeutics beat or miss consensus estimates last quarter?What guidance did Tango Therapeutics's management provide for the next earnings period?What were the key takeaways from Tango Therapeutics’s earnings call?
